The inherited genetics of ovarian and endometrial cancer

Current Opinion in Genetics and Development

Volumn 20, Issue 3, 2010, Pages 231-238

  Gayther, Simon A ^a   Pharoah, Paul D P ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; MISMATCH REPAIR PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

CANCER GENETICS; CANCER RISK; CARCINOGENESIS; ENDOMETRIUM CANCER; FAMILY HISTORY; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HUMAN; INHERITANCE; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; ENDOMETRIUM TUMOR; FAMILY HEALTH; FEMALE; GENETICS; OVARY TUMOR; PENETRANCE; PROCEDURES;

ENDOMETRIAL NEOPLASMS; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; OVARIAN NEOPLASMS; PENETRANCE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 77953615401     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2010.03.001     Document Type: Review

References (56)

1. Stratton J.F., Pharoah P.D.P., Smith S.K., Easton D.F., Ponder B.A.J. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 1998, 105:493-499.
2. Gruber S.B., Thompson W.D. A population-based study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group. Cancer Epidemiol Biomarkers Prev 1996, 5(6):411-417.
3. Lucenteforte E., Talamini R., Montella M., Dal Maso L., Pelucchi C., Franceschi S., La Vecchia C., Negri E. Family history of cancer and the risk of endometrial cancer. Eur J Cancer Prev 2009, 18(2):95-99.
4. Parazzini F., Negri E., La Vecchia C., Restelli C., Franceschi S. Family history of reproductive cancers and ovarian cancer risk: an Italian case-control study. Am J Epidemiol 1992, 135(1):35-40.
5. Lichtenstein P., Holm N.V., Verkasalo P.K., Iliadou A., Kaprio J., Koskenvuo M., Pukkala E., Skytthe A., Hemminki K. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark and Finland. N Engl J Med 2000, 343(2):78-85.
6. Meyer L.A., Broaddus R.R., Lu K.H. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 2009, 16(1):14-22.
7. Aarnio M., Sankila R., Pukkala E., Salovaara R., Aaltonen L.A., de la Chapelle A., Peltomäki P., Mecklin J.P., Järvinen H.J. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999, 81(2):214-218.
8. Vasen H.F., Watson P., Mecklin J.P., Lynch H.T. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999, 116(6):1453-1456.
9. Watson P., Lynch H.T. Cancer risk in mismatch repair gene mutation carriers. Fam Cancer 2001, 1:57-60.
10. Watson P., Vasen H.F., Mecklin J.P., Bernstein I., Aarnio M., Järvinen H.J., Myrhøj T., Sunde L., Wijnen J.T., Lynch H.T. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008, 123(2):444-449.
11. Vasen H.F.A., Stormorken A., Menko F.H., Nagengast F.M., Kleibeuker J.H., Griffioen G., Taal B.G., Moller P., Wijnen J.T. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001, 19:4074-4080.
12. de la Chapelle A. The incidence of Lynch syndrome. Fam Cancer 2005, 4:233-237.
13. Hampel H., Frankel W.L., Martin E., Arnold M., Khanduja K., Kuebler P., Nakagawa H., Sotamaa K., Prior T.W., Westman J., et al. Screening for the Lynch syndrome (hereditary non polyposis colorectal cancer). N Engl J Med 2005, 352:1851-1860.
14. Malander S., Rambech E., Kristoffersson U., Halvarsson B., Ridderheim M., Borg A., Nilbert M. The contribution of the hereditary non polyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol 2006, 101:238-243.
15. Rubin S.C., Blackwood M.A., Bandera C., Behbakht K., Benjamin I., Rebbeck T.R., Boyd J. BRCA1, BRCA2, and hereditary non polyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 1998, 178:670-677.
16. Lu K.H., Schorge J.O., Rodabaugh K.J., Daniels M.S., Sun C.C., Soliman P.T., White K.G., Luthra R., Gershenson D.M., Broaddus R.R. Prospective determination of prevalence of Lynch syndrome in young women with endometrial cancer. J Clin Oncol 2007, 25:5158-5164.
17. Berends M.J., Wu Y., Sijmons R.H., van der Sluis T., Ek W.B., Ligtenberg M.J., Arts N.J., ten Hoor K.A., Kleibeuker J.H., de Vries E.G., et al. Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol 2003, 21:4364-4370.
18. Ollikainen M., Abdel-Rahman W.M., Moisio A.L., Lindroos A., Kariola R., Järvelä I., Pöyhönen M., Butzow R., Peltomäki P. Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary non polyposis colorectal cancer or a separate syndrome?. J Clin Oncol 2005, 23:4609-4616.
19. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 2000, 37:828-830.
20. Cantley L.C., Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1999, 96:4240-4245.
21. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997, 15:356-362.
22. Black D., Bogomolniy F., Robson M.E., Offit K., Barakat R.R., Boyd J. Evaluation of germline PTEN mutations in endometrial cancer patients. Gynecol Oncol 2005, 96(January (1)):21-24.
23. Ford D., Easton D.F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D.T., Weber B., Lenoir G., Chang-Claude J., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. American Journal of Human Genetics 1998, 62(3):676-689.
24. Gayther S.A., Russell P., Harrington P., Antoniou A., Easton D.F., Ponder B.A.J. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet 1999, 65:1021-1029.
25. Ramus S.J., Harrington P.A., Pye C., Dicioccio R.A., Cox M.J., Garlinghouse-Jones K., Oakley-Girvan I., Jacobs I.J., Hardy R.M., Whittemore A.S., et al. Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum Mutat 2007, 28(12):1207-1215.
26. Ramus S.J., Gayther S.A. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol 2009, 3(2):138-150.
27. Antoniou A., Pharoah P., Narod S., Risch H., Eyfjord J., Hopper J., Loman N., Olsson H., Johannsson O., Borg A., et al. Average risks of breast and ovarian cancer associated with mutations in BRCA1 or BRCA2 detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72:1117-1131.
28. Antoniou A.C., Sinilnikova O.M., Simard J., Leone M., Dumont M., Neuhausen S.L., Struewing J.P., Stoppa-Lyonnet D., Barjhoux L., Hughes D.J., et al. Chenevix-Trench G. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 2007, 81(6):1186-1200.
29. Antoniou A.C., Spurdle A.B., Sinilnikova O.M., Healey S., Pooley K.A., Schmutzler R.K., Versmold B., Engel C., Meindl A., Arnold N., et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008, 82(4):937-948.
30. Antoniou A.C., Easton D.F. Risk prediction models for familial breast cancer. Future Oncol 2006, 2(2):257-274.
31. Pearce C.L., Wu A.H., Gayther S.A., Bale A.E., Beck P.A., Beesley J., Chanock S., Cramer D.W., Dicioccio R., Edwards R., et al. Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the ovarian cancer association consortium pooled analysis. Br J Cancer 2008, 98(2):282-288.
32. Schildkraut J.M., Goode E.L., Clyde M.A., Iversen E.S., Moorman P.G., Berchuck A., Marks J.R., Lissowska J., Brinton L., Peplonska B., et al. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res 2009, 69(6):2349-2357.
33. Gayther S.A., Song H., Ramus S.J., Kjaer S.K., Whittemore A.S., Quaye L., Tyrer J., Shadforth D., Hogdall E., Hogdall C., et al. Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res 2007, 67(7):3027-3035.
34. Fasching P.A., Gayther S., Pearce L., Schildkraut J.M., Goode E., Thiel F., Chenevix-Trench G., Chang-Claude J., Wang-Gohrke S., Ramus S., et al. Role of genetic polymorphisms and ovarian cancer susceptibility. Mol Oncol 2009, 3(2):171-181.
35. Meyer L.A., Westin S.N., Lu K.H., Milam M.R. Genetic polymorphisms and endometrial cancer risk. Expert Rev Anticancer Ther 2008, 8(7):1159-1167.
36. Easton D.F., Eeles R.A. Genome-wide association studies in cancer. Hum Mol Genet 2008, 17(R2):R109-R115.
37. Berchuck A., Schildkraut J.M., Pearce C.L., Chenevix-Trench G., Pharoah P.D. Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium. Adv Exp Med Biol 2008, 622:53-67.
38. Song H., Ramus S.J., Tyrer J., Bolton K.L., Gentry-Maharaj A., Wozniak E., Anton-Culver H., Chang-Claude J., Cramer D.W., DiCioccio R., et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 2009, 41(9):996-1000.
39. Lakhani S.R., Manek S., Penault-Llorca F., Flanagan A., Arnout L., Merrett S., McGuffog L., Steele D., Devilee P., Klijn J.G., et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004, 10(7):2473-2481.
40. Rubin S.C., Benjamin I., Behbakht K., Takahashi H., Morgan M.A., LiVolsi V.A., Berchuck A., Muto M.G., Garber J.E., Weber B.L., et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996, 335(19):1413-1416.
41. Domanska K., Malander S., Masback A., Nilbert M. Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40. Int J Gynecol Cancer 2007, 17(4):789-793.
42. Ramus S.J., Pharoah P.D., Harrington P., Pye C., Werness B., Bobrow L., Ayhan A., Wells D., Fishman A., Gore M., et al. BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases. Cancer Res 2003, 63(2):417-423.
43. Schmeler K.M., Lynch H.T., Chen L.M., Munsell M.F., Soliman P.T., Clark M.B., Daniels M.S., White K.G., Boyd-Rogers S.G., Conrad P.G., et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006, 354:261-269.
44. Antoniou A.C., Hardy R., Walker L., Evans D.G., Shenton A., Eeles R., Shanley S., Pichert G., Izatt L., Rose S., et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 2008, 45(July (7)):425-431.
45. Wijnen J.T., Vasen H.F., Khan P.M., Zwinderman A.H., van der Klift H., Mulder A., Tops C., Møller P., Fodde R. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 1998, 339:511-518.
46. Balmana J, Steyerberg EW, Syngal S: Risk quantifi{ligature}cation for carrying mutations in Lynch syndrome genes. In ASCO Educational Book 2008; 2008:59-64. http://edbook.ascopubs.org/cgi/content/abstract/2008/1/59.
47. Pharoah P.D., Antoniou A.C., Easton D.F., Ponder B.A. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008, 358(26):2796-2803.
48. Menon U., Skates S.J., Lewis S., Rosenthal A.N., Rufford B., Sibley K., Macdonald N., Dawnay A., Jeyarajah A., Bast R.C., Oram D., Jacobs I.J. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005, 23:7919-7926.
49. Menon U., Gentry-Maharaj A., Hallett R., Ryan A., Burnell M., Sharma A., Lewis S., Davies S., Philpott S., Lopes A., et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009, 10(April (4)):327-340.
50. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M.J., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361(2):123-134.
51. Dunlop M.G., Farrington S.M., Carothers A.D., Wyllie A.H., Sharp L., Burn J., Liu B., Kinzler K.W., Vogelstein B. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997, 6(1):105-110.
52. Vasen H.F., Wijnen J.T., Menko F.H., Kleibeuker J.H., Taal B.G., Griffioen G., Nagengast F.M., Meijers-Heijboer E.H., Bertario L., Varesco L., et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996, 110(4):1020-1027.
53. Hendriks Y.M., Wagner A., Morreau H., Menko F., Stormorken A., Quehenberger F., Sandkuijl L., Møller P., Genuardi M., Van Houwelingen H., et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004, 127(1):17-25.
54. Hampel H., Stephens J.A., Pukkala E., Sankila R., Aaltonen L.A., Mecklin J.P., de la Chapelle A. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005, 129(2):415-421.
55. Baglietto L., Lindor N.M., Dowty J.G., White D.M., Wagner A., Gomez Garcia E.B., Vriends A.H., Cartwright N.R., Barnetson R.A. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst 2010, 102(February (3)):193-201. Dutch Lynch Syndrome Study Group.
56. Choi Y.H., Cotterchio M., McKeown-Eyssen G., Neerav M., Bapat B., Boyd K., Gallinger S., McLaughlin J., Aronson M., Briollais L. Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario. Hered Cancer Clin Pract 2009, 7(August (1)):14.